Peripheral blood progenitor cells (PBPC) are being investigated as an alternative stem cell source in allogeneic transplantation. The current paper presents a 'state-of-the-art' review of HLA-identical sibling transplants (PBPCT). Medline search and meeting reports were used to identify the latest reports from the various transplant centers. The data are presented systematically with the goal of providing a basis for evidencebased medicine. This approach offered the opportunity to identify threshold CD34 ؉ cell numbers for rapid engraftment, threshold CD3
Transplants using circulating hematopoietic cells collected by leukapheresis were initially reported in the early 1980s. [1] [2] [3] [4] Low steady-state circulating PBPC numbers discouraged their use until hematopoietic growth factors became available in the late 1980s with the capacity to mobilize PBPC and facilitate collection. [5] [6] [7] [8] [9] [10] Rapid engraftment suggested the use of PBPC instead of bone marrow and PBPC have now largely replaced BM in autologous transplantation. [11] [12] [13] [14] [15] [16] [17] [18] Ethical concerns about long-term adverse effects of G-CSF in healthy donors delayed the use of PBPC for allogeneic transplantation until the early 1990s. 19 At the first symposium on Allogeneic PBPC Transplants in Geneva in 1995, these concerns were discussed and the consensus reached was that neither clinical nor laboratory research suggested any long-term sequelae of a short course of G-CSF. 20 G-CSF is currently being used for mobilization of PBPC in adult and pediatric, related and unrelated donors. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The development of an international PBPC donor registry to monitor long-term adverse effects has been recommended. 31 The first allogeneic PBPCT series were published in the mid-1990s. [32] [33] [34] Various groups have reported PBPCT since that time. It is estimated that 4000 to 5000 allogeneic PBPCT have been conducted to date, the majority being HLA-identical sibling transplants for hematological malignancies. A 'state-of-the-art' review of non-manipulated and T cell-depleted HLA-identical PBPCT vs BMT is presented here. The data provide evidence of prognostic factors for outcome parameters. 35, 36 An approach to studying outcome parameters systematically is suggested with emphasis on the most concerning and controversial parameter, chronic GVHD.
HLA-identical sibling transplants using nonmanipulated PBPC

Early single center studies
The first three publications reporting 25 HLA-identical sibling PBPCT suggested feasibility. [32] [33] [34] Subsequent single center studies of at least 50 HLA-identical PBPCT for mainly advanced hematological malignancies indicated fast engraftment with 95 to 100% donor chimerism. [37] [38] [39] [40] A relationship was found between the infused cell dose and the time to engraftment. Korbling et al 26 recommended a threshold of 2.5 ϫ 10 6 CD34 ϩ cells/kg to secure rapid trilineage engraftment. Brown et al 41 confirmed this threshold for neutrophil recovery but suggested a threshold of 5 ϫ 10 6 CD34 ϩ cells/kg to secure a 95% probability of early platelet recovery (Ͼ20 ϫ 10 9 /l by day 15). In a study evaluating engraftment, mixed chimerism was identified in 78% of 23 evaluable BMT recipients at 1 month, 57% at 3 months, 42% at 6 months and 33% at 12 months and in 48% of 23, 29% of 21, 17% of 12 and 25% of eight evaluable PBPCT recipients at similar points in time. 42 Full chimerism occurs at an earlier time after PBPCT than after BMT; mixed chimerism predicts relapse. [42] [43] [44] [45] [46] No significant relationship was found between grade II-IV GVHD and type of GVHD prophylaxis (cyclosporin (CsA) plus methotrexate (MTX) vs steroids), disease status (good vs bad risk), donor-recipient gender match and fresh or frozen/thawed PBPC, whereas age might be of influence (median age Ͻ vs у40 years, P ϭ 0.08). 39 Chronic GVHD occurred significantly more frequently in transplant recipients with prior acute GVHD (P ϭ 0.016) or poor risk disease. 38, 39 Transplant-related mortality occurred in 14 Ϯ 9% of transplant recipients with good risk and in 43 Ϯ 8% with bad risk leukemia. 39 Relapse rates after PBPCT for advanced malignancies were 23% at median 285 days follow-up and 23 Ϯ 6% at 1 year follow-up. 38, 39 Prognosis was not prognostic for relapse. 38, 39 Comparative studies Table 1 shows procedures and results of HLA-identical PBPCT vs BMT with non-manipulated cells. Hematological recovery occurred faster after PBPCT. [47] [48] [49] [50] [51] [52] [53] [54] MTX delayed hematological recovery. 49, 50, 55 Transfusion requirements, days of hospitalization and antibiotic requirements were significantly reduced after PBPCT compared to BMT in three of the five analyses reporting these outcome parameters. [47] [48] [49] 51, 52 Another study reported less regimenrelated toxicity, fewer early deaths and shorter time to discharge in the PBPCT group. 50 The incidence of acute GVHD was comparable after PBPCT and BMT. [47] [48] [49] [50] [51] [52] [53] [54] 56 The probability of acute GVHD appeared dependent on the prophylaxis regimen in 156 patients receiving either CsA plus steroids, FK506 plus steroids or FK506 plus MTX. 57 Grade II-IV GVHD occurred in 46%, 30% and 18% and grade III-IV GVHD in 22%, 13% and 6% of patients assigned to the respective regimens. GVHD prophylaxis was the only factor significant for development of grade II-IV GVHD when correcting for other variables. 57 A trend towards increased risk of chronic GVHD after PBPCT compared to BMT has been reported by various groups. 47, 49, 51 Two years follow-up of the patients reported by Bensinger et al 49 revealed a relative risk of extensive chronic GVHD of 2.37 (1.07-5.29, 95% CI; P ϭ 0.035) after PBPCT compared to BMT. 58 Retrospective analysis of 50 PBPCT with 172 historical BMT controls reported to the International Bone Marrow Transplant Registry revealed a significantly higher probability of chronic GVHD in the PBPCT cohort (P ϭ 0.03). 56 Observations of other groups have not confirmed this trend neither have any of the prospective studies reported to date. 53, 54, 59 Transplant-related mortality, relapse, disease-free and overall survival were comparable after PBPCT and BMT in three analyses of transplants for advanced malignancies. 49, 52, 54 Another study reported 18% and 40% relapse after PBPCT and BMT at 2 years follow-up. 40 Disease status appeared prognostic for transplant-related mortality and survival after PBPCT. 52, 54 HLA-identical sibling transplants using T cell-depleted PBPC Table 2 shows procedures and results of CD34 ϩ selected or CD8
ϩ depleted HLA-identical PBPCT whether or not compared to non-manipulated PBPCT 60, 61 or to T celldepleted BMT. 62, 63 T cell depletion did not interfere with engraftment, which occurred in general rapidly. [60] [61] [62] [63] [64] [65] [66] [67] Ninety-seven to 100% donor chimerism was reported despite 3 to 3.5 logs T cell depletion. 65, 66 MTX delayed the time to neutrophil and platelet recovery 61, 64, 65 and reduced the incidence of acute and chronic GVHD after CD34 ϩ selected PBPCT. 64, 66 Seven of the eight evaluable patients in the study reported by Bensinger et al 66 developed chronic GVHD, which was extensive in two of three (66%) patients receiving CsA only and in one of five (20%) patients receiving CsA plus MTX. CsA plus MTX prevented severe acute and chronic GVHD in other cases receiving CD34 ϩ selected PBPCT. 61, 65 T cell depletion decreased the incidence of acute GVHD in two studies comparing T cell-depleted with non-depleted PBPCT. 60, 61 A retrospective comparison of T cell-depleted PBPCT with T cell-depleted BMT revealed comparable probabilities of acute GVHD and a trend towards an increased incidence of chronic GVHD in the PBPCT cohort. 63 The infused T cell dose was higher in PBPCT recipients and relapse occurred more frequently at 18 months follow-up in the BMT (29%) than PBPCT (9%) cohort. 63 Transplant-related mortality was 20% in patients with early advanced and 44% in patients with very advanced disease. 66, 67 CD8 ϩ depletion of BM and blood resulted in comparable probabilities of acute GVHD, disease-free and overall survival. 
Conclusion of observations
More rapid engraftment, full donor chimerism and immune reconstitution occur after non-manipulated PBPCT than after BMT. T cell depletion does not interfere with engraftment.
The risk of grade II-IV GVHD is 35-50% after standard and 15-25% after T cell-depleted HLA-identical sibling BMT. [68] [69] [70] [71] [72] [73] Comparable risks of acute GVHD are observed after non-manipulated and T cell-depleted PBPCT, respectively, when either combination drug prophylaxis or threshold T cell doses of 4 to 5 ϫ 10 5 CD3 ϩ cells/kg combined with CsA are administered. 60, 61, 63, 65, 67 Combination drug prophylaxis seems warranted when the T cell dose exceeds this threshold. 64, 66 Combination drug prophylaxis after infusion of this threshold T cell dose eliminates grade III-IV GVHD. 60, 61, 65, 67 The suggested threshold requires confirmation as a lower threshold of 1 ϫ 10 5 CD3 ϩ cells/kg has been recommended in BMT. 74 The risk of chronic GVHD after HLA-identical sibling transplants is 25-60%. Most retrospective comparative studies suggest a trend towards a significantly higher risk of chronic GVHD after PBPCT than BMT but this observation has not been consistent. 39, 47, [51] [52] [53] 56, 58, 63, [75] [76] [77] Comparable relapse rates were reported in most retrospective studies reporting non-manipulated transplants 49, 50, 52, 54 with the exception of an analysis indicating lower relapse rates after PBPCT and another analysis reporting less frequent relapse in recipients of T cell-depleted PBPCT (9%) compared to BMT (29%). 40, 63 Treatment-related mortality, disease-free and overall survival were comparable between PBPCT and BMT. 
Discussion
This review comparing non-manipulated or T cell-depleted PBPCT with BMT indicates more rapid engraftment, full donor chimerism and faster immune reconstitution after non-manipulated PBPCT compared to BMT. 52, 78, 79 The effect of partial T cell depletion (3 logs) of PBPC grafts on immune reconstitution remains to be examined. Partial T cell depletion of BM did not induce clinically apparent differences in immune reconstitution. 80 Acute GVHD occurs at comparable incidence after transplants of either cell source despite the 10-fold higher T cell content of PBPC grafts. [47] [48] [49] [50] 53, 62, 81, 82 One explanation might be the difference in composition of T cell fractions of PBPC and BM harvests; T cell subsets suppressing the mixed leukocyte response (CD4 CD8 ␣␤ T cells) occur more frequently in PBPC grafts. 82 This difference in immunogenicity may explain the higher threshold T dose inducing acute GVHD after PBPCT (4 to 5 ϫ 10 5 CD3 ϩ cells/kg) than after BMT (1 ϫ 10 5 CD3 ϩ cells/kg). 60, 61, [63] [64] [65] [66] [67] 74 Relapse rates after PBPCT do not exceed those after BMT. 40, 49, 50, 52, 54, 63, 83 This may partially be explained by the fact that a higher CD4
ϩ /CD8 ϩ cell ratio occurs in PBPC than BM grafts. 84 Furthermore, rapid recovery of the CD4 ϩ /CD8 ϩ T cell ratio and more rapid overall immune reconstitution may enhance the GVL effect after PBPCT. 52, 79, 85 The fact that full donor chimerism occurs earlier and more frequently after PBPCT is a third explanation for less relapse. [42] [43] [44] [45] [46] Most controversy and concern exist about the trend towards a higher incidence of chronic GVHD after PBPCT. Prognostic factors for chronic GVHD in BMT are prior acute GVHD, age, non T cell-depleted grafts, steroid use before transplant and at day 100 post-transplant, red cell transfusions pretransplant, recipient and donor CMV seropositivity. [86] [87] [88] [89] [90] [91] [92] [93] [94] The question arises which factors are predictive for chronic GVHD after PBPCT and whether chronic GVHD indeed occurs at higher frequency after PBPCT compared to BMT. Acute GVHD is a risk factor but not predictive for acute GVHD after PBPCT. 51, 76 The data suggest that MTX and T cell depletion reduce the risk of chronic GVHD after PBPCT. 49, 51, [63] [64] [65] [66] [67] 
Future clinical research
The evidence provided by these data can be used to design future studies. Retrospective comparative analyses of PBPCT and BMT with adequate follow-up would be of value to evaluate treatment-related mortality, disease-free and overall survival, whereas randomized studies may be confirmatory. The suggested threshold of 4 to 5 ϫ 10 5
CD3
ϩ cells/kg to prevent acute GVHD requires confirmation. Investigation of chronic GVHD is important: retrospective analysis may introduce the bias of inconsistent clinical evaluation and laboratory procedures by the various centers contributing data. Randomized studies with chronic GVHD as the secondary endpoint have as of yet not been confirmatory. 53, 54, 59 Studying a specific outcome parameter requires the parameter to become the primary study endpoint. To reduce interpretation bias of chronic GVHD, standardization of clinical scoring and laboratory assessment is required. Systematic clinical research of chronic GVHD would furthermore involve: single arm T cell dosing studies of adequate sample size per dose level, identification of prognostic factors and stratification for prognostic factors with impact, and definition of the minimal (2.5 ϫ 10 6 ) and optimal (5 ϫ 10 6 ) CD34
ϩ cell/kg content of the graft. 26, 41 T cell depletion with T cell add-back to titrate the desired T cell dose could be used in dosing. Concurrent evaluation of other outcome parameters would indicate the dosing effect on these parameters. The results of these studies should define the need for subsequent randomized studies.
In conclusion, systematic review of published data provides information and evidence for planning future prospective studies to answer questions and solve controversies.
